Store
Precision Cancer Therapeutics, 2022
Publication Date: October 25, 2022
Tags: CAR-T Cell Therapy, Oncology and Cancer, Personalized Medicine, Precision Oncology
Pages: 150
SKU: 22-719
Precision Cancer Therapeutics, 2022 examines the current landscape of precision therapies, the significant impact they are making, and the exciting developments on the horizon. Kalorama Information has monitored the cancer treatment market for over two decades and continues to provide valuable insights into the impact of new technologies. This report is essential for understanding the expanding area of precision cancer therapies and staying informed about current products and upcoming developments.
Report Highlights:
- Global Cancer Impact:
- Cancer continues to affect approximately 18.1 million people annually, leading to significant loss of life and financial burden.
- Between 35 and 40 million people are living with cancer worldwide, with nearly 10 million annual deaths.
- The most common cancers include lung, breast, colon/rectum, stomach, liver, prostate, cervical, esophageal, and bladder.
- Precision Cancer Therapies:
- Advanced precision cancer therapies are less invasive, less damaging, and promise improved outcomes.
- The report focuses on five leading segments of precision therapies:
- Monoclonal antibodies
- Kinase inhibitors
- Angiogenesis inhibitors
- Proteasome inhibitors
- CAR-T therapies
- Additionally, smaller areas of precision therapies are covered, including mTOR inhibitors, PI3K inhibitors, PARP inhibitors, apoptosis inhibitors, histone deacetylase inhibitors, CDK inhibitors, and hedgehog signaling pathway inhibitors.
Scope and Methodology:
- Comprehensive Market Analysis:
- The report covers precision cancer therapies that:
- Block or turn off chemical signals that tell the cancer cell to grow and divide.
- Change proteins within the cancer cells so the cells die.
- Stop making new blood vessels to feed the cancer cells.
- Trigger the immune system to kill the cancer cells.
- Carry toxins to the cancer cells to kill them without harming normal cells.
- The report covers precision cancer therapies that:
- Detailed Statistical Information:
- Statistical data for various types of cancers on a global level.
- Profiles of cancers with current products available or in development, and those with significant incidence/mortality rates.
- Market Insights:
- Overview of disease epidemiology, leading product sales, market estimates and forecasts, and a competitive summary of leading providers.
- A list of Phase 3 precision therapies in development.
- Discussion of market indicators, trends, and barriers.
Table: Cancer Treatment mAb Market, by Type, 2022-2027 (in millions $)
| Type | 2022 | 2027 | CAGR 2022-2027 |
| Breast Cancer | $XX Million | $XX Million | XX% |
| Colorectal Cancer | $XX Million | $XX Million | XX% |
| Lymphoma | $XX Million | $XX Million | XX% |
| Leukemia | $XX Million | $XX Million | XX% |
| Myeloma | $XX Million | $XX Million | XX% |
| Melanoma | $XX Million | $XX Million | XX% |
| Lung Cancer | $XX Million | $XX Million | XX% |
| Renal Cancer | $XX Million | $XX Million | XX% |
| Urothelial Cancer | $XX Million | $XX Million | XX% |
Source: Kalorama Information
For further details and to purchase directly, please contact us.
Table of Contents
Chapter 1: Executive Summary
Overview
Scope and Methodology
Market Overview and Analysis
- Figure 1-1: Global Precision Cancer Therapeutic Market Size and Forecast, 2017-2027 ($millions)
Chapter 2: Introduction
Global Cancer Burden
- Figure 2-1: Incidence of Cancer by Type, 2020
- Figure 2-2: Distribution of Cancer Incidence by Type, 2020
Introduction to Cancer
Biochemistry of Cancer Cells
Causes of Cancer Growth May Shed Light on Treatment
Environmental Factors, DNA, RNA
- Table 2-1: Virus Association with Human Cancer
Cellular Oncogenes
Tumor Suppressor Genes
Cancer Treatment Approaches
- Table 2-2: Characteristics of Cancer Treatment Approaches (chemotherapy, hormone therapy, Precision therapy)
What is Precision Cancer Therapy?
Trends in Research and Development of Precision Cancer Therapeutics
Monoclonal Antibodies: The Leading Area of Cancer Precision Therapy
Chapter 3: Precision Cancer Therapies: Monoclonal Antibodies
Monoclonal Antibody Overview
Market Outlook
- Figure 3-1: Cancer Monoclonal Antibody Market, 2017-2027 ($ millions)
Principal Products
- Table 3-1: Top 10 Cancer Indicated Monoclonal Antibodies, 2021 and 2022 Sales (millions $)
- Figure 3-2: Top 10 Cancer Indicated Monoclonal Antibodies, 2021 and 2022 Sales (millions $)
Avastin (bevacizumab)
Blincyto (blinatuomab)
Darzalex (daratumumab)
Erbitux (cetuximab)
Herceptin (trastuzumab)
Kadcyla (ado-trastuzumab emtansine)
Keytruda (pembrolizumab)
Libtayo (cemiplimab-rwlc)
Opdivo (nivolumab)
Padcev (enfortumab vedotin-jfv)
Perjeta (pertuzumab)
Rituxan (rituximab)
Sarclisa (isatuximab)
Tivdak (tisolumab vedotin-tftv)
Tecentriq (atezolizumab)
Vectibix (panitumumab)
Xgeva (denosumab)
Yervoy (ipilimumab)
- Table 3-2: Selected Monoclonal Antibodies in Cancer Therapy
Late-Stage Monoclonal Antibodies Development
- Table 3-3: Selected Late-Stage Monoclonal Antibodies in Phase 3 Development
Market Breakdown of Monoclonal Antibodies
Cancer Monoclonal Antibody Market by Target
- Table 3-4: Cancer Monoclonal Antibody Market by Target, 2022 and Forecast 2027 ($ millions)
- Figure 3-3: Cancer Monoclonal Antibody Market by Target, 2022 and Forecast 2027 ($ millions)
- Figure 3-4: Cancer Monoclonal Antibody Market Distribution by Target, 2022 (%)
- Figure 3-5: Cancer Monoclonal Antibody Market Distribution by Target, 2027 (%)
Cancer Monoclonal Antibody Market by Type
- Figure 3-6: Development of the mAb Cancer Treatment Market, 2010-2027 ($ millions)
- Table 3-5: Cancer Treatment mAb Market by Type, 2022-2027 ($ millions)
- Figure 3-7: Monoclonal Antibody Market by Cancer Type, 2022 and 2027 ($ millions)
- Figure 3-8: Monoclonal Antibody Market, Distribution by Cancer Type, 2022 (%)
- Figure 3-9: Monoclonal Antibody Market Distribution by Indication, 2027 (%)
Regional Market Summary
- Figure: 3-10: Cancer Monoclonal Antibody Market Summary by Geographic Region, 2022 and 2027 ($ millions)
Competitor Summary
Merck & Co.
Genentech/Roche
Bristol-Myers Squibb
Janssen Biotech/J&J
Amgen
AstraZeneca
EMD Serono
- Table 3-6: Cancer Monoclonal Antibody Competitor Market Share – Top Seven, 2022 ($ millions)
Chapter 4: Precision Cancer Therapies: Kinase Inhibitors
Kinase Inhibitor Overview
Market Outlook
- Figure 4-1: Kinase Inhibitor Market, 2022-2027: CAGR 8.8% ($ millions)
Principal Products
- Table 4-1: Top 10 Cancer Indicated Kinase Inhibitors, 2021 and Forecast 2022 Sales (millions $)
- Figure 4-2: Top 10 Cancer Indicated Kinase Inhibitors, 2021 and Forecast 2022 Sales (millions $)
Alecensa (alectinib)
Alunbrig (brigatinib)
Imbruvica (ibrutinib)
Inlyta (axitinib)
Sprycel (dasatinib)
Tasigna (nilotinib)
Tagrisso (osimertinib)
Gleevec (imatinib)
Mekinist+Tafinlar (trametinib + dabrafenib)
Sutent (sunitinib)
Jakafi/Jakavi (ruxolitinib)
Nexavar (sorafenib)
Tukysa (tucatinib)
Votrient (pazopanib)
- Table 4-2: Kinase Inhibitors in Cancer Therapy
Late-Stage Kinase Inhibitors Development
- Table 4-3: Selected Phase 3 Kinase Inhibitors in Development
Market Breakdown of Kinase Inhibitors
Cancer Kinase Inhibitor Market by Target
- Table 4-4: Cancer Kinase Inhibitor Market by Target, 2022 and Forecast 2027 ($ millions)
- Figure 4-3: Cancer Kinase Inhibitor Market by Target, 2022 and 2027 ($ millions)
- Figure 4-4: Kinase Inhibitor Market Distribution by Target, 2022 (%)
- Figure 4-5: Kinase Inhibitor Market Distribution by Target, 2027 (%)
Cancer Kinase Inhibitor Market by Type
- Figure 4-6: Development of the Kinase Inhibitor Cancer Treatment Market, 2010-2027 ($ millions)
- Table 4-5: Cancer Treatment Kinase Inhibitor Market by Type, 2022-2027 ($ millions)
- Figure 4-7: Kinase Inhibitor Market by Cancer Indication, 2022 and 2027 ($ millions)
- Figure 4-8: Kinase Inhibitor Market Distribution by Cancer Indication, 2022 (%)
- Figure 4-9: Kinase Inhibitor Market Distribution by Cancer Indication, 2027 (%)
Regional Market Summary
- Figure: 4-10: Cancer Kinase Inhibitor Market Summary by Geographic Region, 2022 and 2027 ($ millions)
Competitor Summary
Novartis
AstraZeneca
AbbVie
Johnson & Johnson
Pfizer
Bristol-Myers Squibb
Roche/Genentech
- Table 4-6: Cancer Kinase Inhibitor Competitor Market Share, 2022 ($ millions)
Chapter 5: Precision Cancer Therapies: Angiogenesis Inhibitors
Angiogenesis Inhibitor Overview
Market Outlook
- Figure 5-1: Angiogenesis Inhibitor Market, 2017-2027 ($ millions)
Principal Products
Pomalyst/Imnovid (pomalidomide)
Revlimid (lenalidomide)
Thalomid (thalidomide)
Zaltrap (ziv-aflibercept)
- Table 5-1: Angiogenesis Inhibitors in Cancer Therapy
Late-Stage Angiogenesis Inhibitor Phase 3 Development
- Table 5-2: Selected Phase 3 Angiogenesis Inhibitor Development
Regional Market Summary
- Figure: 5-2: Cancer Angiogenesis Inhibitor Market Summary by Geographic Region, Estimated 2022 and 2027 ($ millions)
Competitor Summary
Chapter 6: Precision Cancer Therapies: CAR-T Therapies
CAR-T Overview
Manufacturing Process for CAR-T
Leukapheresis
Activation
Transduction
Expansion
Regulatory Developments
Market Outlook
- Figure 6-1: CAR-T Market, 2017-2027 ($ millions)
Principal Products
Abecma
Breyanzi
Carvykti
Kymriah
Tecartus
Yescarta
Late-Stage CAR-T Therapies Development
- Table 6-1: Phase III Development ¾ CAR-T Therapies, Select Projects
Regional Market Summary
- Figure: 6-2: Cancer CAR-T Market Summary by Geographic Region, Estimated 2022 and 2027 ($ millions)
Competitor Summary
Chapter 7: Precision Cancer Therapies: Proteasome Inhibitors
Proteasome Inhibitor Overview
Market Outlook
- Figure 7-1: Proteasome Inhibitor Market, 2022-2027 ($ millions)
Principal Products
Kyprolis (carfilzomib)
Ninlaro (ixazomib)
Velcade (bortezomib)
- Table 7-1: Proteasome Inhibitors in Cancer Therapy
Regional Market Summary
- Figure 7-2: Cancer Proteasome Inhibitor Market Summary by Geographic Region, Estimated 2022 and 2027 ($ millions)
Competitor Summary
Takeda
Amgen
- Table 7-2: Cancer Proteasome Inhibitor Competitor Market Share, 2022 ($ millions)
Chapter 8: Precision Cancer Therapies: Other Precision Therapies
Other Precision Therapies Overview
Market Outlook
- Figure 8-1: Other Precision Therapies Market, 2017-2027 ($ millions)
Principal Products
mTOR Inhibitor ¾ Afinitor (everolimus)
mTOR Inhibitor ¾ Torisel (temsirolimus)
PI3K Inhibitor ¾ Zydelig
PARP Inhibitor ¾ Lynparza
PARP Inhibitor ¾ Zejula
Apoptosis Inducer ¾ Venclexta
CDK Inhibitors – Ibrance (palbociclib)
CDK Inhibitors – Kisqali (ribociclib)
- Table 8-1: Other Precision Cancer Therapies
Late-Stage Other Therapies Development
- Table 8-2: Select Phase 3 Other Therapies Development
Regional Market Summary
- Figure: 8-2: Other Precision Therapies Market Summary by Geographic Region, Estimated 2022 and 2027 ($ millions)
Chapter 9: Market Summary
Market Influences
Global Demographics
- Table 9-1: Global Population, through 2050 (population in millions)
Aging Population
- Figure 9-1: Global Population Trends, Total Population vs. Age 65+ Population, 2000-2050
Cancer: A Growing Economic Burden
Cost Containment
- Table 9-2: The Cost of Monoclonal Antibodies (2020-2021)
Reimbursement Landscape: A Deciding Factor for Success
The Biosimilar Movement
Regional Market Overview
- Table 9-3: Precision Cancer Therapeutics Market Summary by Geographical Region, 2022-2027 ($ millions)
United States and Canada
- Table 9-4: Precision Cancer Therapeutics Market Summary for U.S. and Canada, 2022-2027 ($ millions)
- Figure 9-2: Precision Cancer Therapeutics for U.S. and Canada, Distribution by Therapy Type (monoclonal antibodies, kinase inhibitors, angiogenesis inhibitors, proteasome inhibitors, CAR-T, other Precision therapies), 2022 %
EMEA
- Table 9-5: Precision Cancer Therapeutics Market Summary for EMEA, 2022-2027 ($ millions)
- Figure 9-3: Precision Cancer Therapeutics for EMEA, Distribution by Therapy Type (monoclonal antibodies, kinase inhibitors, angiogenesis inhibitors, proteasome inhibitors, CAR-T, other Precision therapies), 2022 (%)
Asia Pacific
- Table 9-6: Precision Cancer Therapeutics Market Summary for Asia Pacific, 2022-2027 ($ millions)
- Figure 9-4: Precision Cancer Therapeutics for Asia Pacific, Distribution by Therapy Type (monoclonal antibodies, kinase inhibitors, angiogenesis inhibitors, proteasome inhibitors, CAR-T, other Precision therapies), 2022 (%)
Latin America
- Table 9-7: Precision Cancer Therapeutics Market Summary for Latin America, 2022-2027 ($ millions)
- Figure 9-5: Precision Cancer Therapeutics for Latin America, Distribution by Therapy Type (monoclonal antibodies, kinase inhibitors, angiogenesis inhibitors, proteasome inhibitors, CAR-T, other Precision therapies), 2022 (%)
Chapter 10: Market Participants
Top 15 Overview
- Table 10-1: Global Market Participants for Precision Cancer Therapeutics, Top 15 Companies, 2022 ($ in millions)
- Figure 10-1: Global Market Share for Precision Cancer Therapeutics, 2022 %
- Figure 10-2: Growth in Precision Cancer Therapeutics by Company 2010 vs. 2022 ($ in millions)
- Figure 10-3: Growth Trend by Company, 2010-2022 CAGR: Precision Cancer Therapeutics
AbbVie, Inc.
- Table 10-2: AbbVie Corporate Summary
Company Summary
Amgen
- Table 10-3: Amgen Corporate Summary
Company Summary
Astellas Pharma U.S., Inc
- Table 10-4: Astellas Corporate Summary
Company Summary
AstraZeneca PLC
- Table 10-5: AstraZeneca Corporate Summary
Company Summary
Bayer AG
- Table 10-6: Bayer Corporate Summary
Company Summary
Bristol-Myers Squibb Company
- Table 10-7: Bristol-Myers Squibb Corporate Summary
Company Summary
Clovis Oncology, Inc.
- Table 10-8: Clovis Oncology Corporate Summary
Company Summary
Dendreon Pharmaceuticals LLC
- Table 10-9: Dendreon Corporate Summary
Company Summary
Eli Lilly & Company
- Table 10-10: Eli Lilly Corporate Summary
Company Summary
EMD Serono, Inc. (Merck KgaA)
- Table 10-11: EMD Serono Corporate Summary
Company Summary
Eisai Co., Ltd.
- Table 10-12: Eisai Corporate Summary
Company Summary
Exelixis, Inc.
- Table 10-13: Exelixis Corporate Summary
Company Summary
Gilead Sciences, Inc.
- Table 10-14: Gilead Sciences Corporate Summary
Company Summary
GlaxoSmithKline
- Table 10-15: GSK Corporate Summary
Company Summary
Johnson & Johnson
- Table 10-16: Johnson & Johnson Corporate Summary
Company Summary
Merck & Co., Inc.
- Table 10-17: Merck & Co. Corporate Summary
Company Summary
Novartis AG
- Table 10-18: Novartis Corporate Summary
Company Summary
Otsuka Holdings Co., Ltd.
- Table 10-19: Otsuka Corporate Summary
Company Summary
Pfizer, Inc.
- Table 10-20: Pfizer Corporate Summary
Company Summary
Puma Biotechnology, Inc.
- Table 10-21: Puma Biotechnology Corporate Summary
Company Summary
Roche (F. Hoffman-La Roche, Ltd.)
- Table 10-22: Roche Corporate Summary
Company Summary
Sanofi/Genzyme
- Table 10-23: Sanofi/Genzyme Corporate Summary
Company Summary
Seagen Inc.
- Table 10-24: Seagen Corporate Summary
Company Summary
Takeda Oncology – Millennium Pharmaceuticals
- Table 10-25: Takeda Oncology Corporate Summary
Company Summary
Related products
Clinical Laboratory Services Market, 8th Edition
May 18, 2023
Laboratories are the workhorse of diagnostic services for the IVD market. These laboratories play a vital role in providing analysis of a wide range of disorders and diseases including pathology, immunology, cholesterol testing, allergy testing, urinalysis, genetic testing and many more. Kalorama Information’s Clinical Laboratory Services Market, 8th Edition is your comprehensive resource for insights…
$4,000.00 – $6,000.00
The Worldwide Market for Point-of-Care (POC) Diagnostic Tests, 11th Edition
April 23, 2024
Explore the latest trends and forecasts in the point-of-care (POC) diagnostic tests market with Kalorama Information’s The Worldwide Market for Point-of-Care (POC) Diagnostic Tests, 11th Edition. Discover the key growth areas and technological advancements shaping the future of POC diagnostics.
Lab-based analyzers in hospitals and reference labs are the cornerstone of revenues in the in…
$7,000.00 – $10,000.00
The World Market for Vaccines, 2024
February 22, 2024
Vaccines are a cornerstone of preventive medicine, offering long-term or permanent immunity against diseases. They have been instrumental in near-eliminating many deadly diseases, making vaccination one of the greatest public health achievements of the 20th century. Kalorama Information’s latest report, The World Market for Vaccines, 2024, provides a comprehensive analysis of adult…
$5,000.00 – $7,875.00
